Theoretical and Clinical Geropharmacology, explores the emerging field of senotherapeutics, which focuses on targeting cellular senescence to reduce age-related diseases and promote healthy aging. Chapters in this new release include Senotherapeutics: Milestones, innovations, and future prospects, Game Changer: Navigating between challenges and hopes in Geropharmacology, Next-Gen Senotherapeutics: AI/ML-driven strategies for aging and age-related disorders, Pharmacological frontiers in senescence: Transforming senescence with drug repurposing, Pharmacological potential of calorie restriction mimetics in mitigating brain aging, Isothiocyanates from cruciferous plants as geroprotectors, and much more.
Other chapters cover Cellular parabiosis as a senotherapeutic approach, Molecular imaging for senescent cells-targeted therapeutics in aging and age-related diseases, Mitochondria-associated membranes (MAMs) in age-related heart diseases, role of endoplasmic reticulum stress, Cellular senescence and senotherapeutics in cardiovascular diseases, Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients, Geropharmacology and gastrointestinal surgery, Oxygen-ozone adjunct therapy in aging and senescence-related disorders, and more.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xv 6. Preface - p. xix 7. Brief Biography of Senior Editor - p. xxi 8. Chapter One: Senotherapeutics: Milestones, innovations, and future prospects - p. 1 9. Chapter Two: Game changer: Navigating between challenges and hopes in geropharmacology - p. 37 10. Chapter Three: Next-gen senotherapeutics: AI/ML-driven strategies for aging and age-related disorders - p. 87 11. Chapter Four: Pharmacological frontiers in senescence: Transforming senescence with drug repurposing - p. 121 12. Chapter Five: Pharmacological potential of calorie restriction mimetics in mitigating brain aging - p. 177 13. Chapter Six: Isothiocyanates from cruciferous plants as geroprotectors - p. 199 14. Chapter Seven: Cellular parabioisis as a senotherapeutic approach - p. 227 15. Chapter Eight: Molecular imaging for senescent cells-targeted therapeutics in aging and age-related diseases - p. 259 16. Chapter Nine: Mitochondria-associated membranes (MAMs) in age-related heart diseases, role of endoplasmic reticulum stress - p. 289 17. Chapter Ten: Cellular senescence and senotherapeutics in cardiovascular diseases - p. 313 18. Chapter Eleven: Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients - p. 351 19. Chapter Twelve: Geropharmacology and gastrointestinal surgery - p. 393 20. Chapter Thirteen: Oxygen-ozone adjunct therapy in aging and senescence-related disorders. State of art - p. 417 21. Chapter Fourteen: Polypharmacy-induced changes in the oral mucosa and jawbone in elderly - p. 447 22. Chapter Fifteen: Senotherapeutic approach to age-related endocrine diseases - p. 475 23. Chapter Sixteen: Polypharmacy as a reason for misinterpreting laboratory results in the elderly - p. 515
Theoretical and Clinical Geropharmacology, explores the emerging field of senotherapeutics, which focuses on targeting cellular senescence to reduce age-related diseases and promote healthy aging. Chapters in this new release include Senotherapeutics: Milestones, innovations, and future prospects, Game Changer: Navigating between challenges and hopes in Geropharmacology, Next-Gen Senotherapeutics: AI/ML-driven strategies for aging and age-related disorders, Pharmacological frontiers in senescence: Transforming senescence with drug repurposing, Pharmacological potential of calorie restriction mimetics in mitigating brain aging, Isothiocyanates from cruciferous plants as geroprotectors, and much more.
Other chapters cover Cellular parabiosis as a senotherapeutic approach, Molecular imaging for senescent cells-targeted therapeutics in aging and age-related diseases, Mitochondria-associated membranes (MAMs) in age-related heart diseases, role of endoplasmic reticulum stress, Cellular senescence and senotherapeutics in cardiovascular diseases, Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients, Geropharmacology and gastrointestinal surgery, Oxygen-ozone adjunct therapy in aging and senescence-related disorders, and more.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Contributors - p. xv 6. Preface - p. xix 7. Brief Biography of Senior Editor - p. xxi 8. Chapter One: Senotherapeutics: Milestones, innovations, and future prospects - p. 1 9. Chapter Two: Game changer: Navigating between challenges and hopes in geropharmacology - p. 37 10. Chapter Three: Next-gen senotherapeutics: AI/ML-driven strategies for aging and age-related disorders - p. 87 11. Chapter Four: Pharmacological frontiers in senescence: Transforming senescence with drug repurposing - p. 121 12. Chapter Five: Pharmacological potential of calorie restriction mimetics in mitigating brain aging - p. 177 13. Chapter Six: Isothiocyanates from cruciferous plants as geroprotectors - p. 199 14. Chapter Seven: Cellular parabioisis as a senotherapeutic approach - p. 227 15. Chapter Eight: Molecular imaging for senescent cells-targeted therapeutics in aging and age-related diseases - p. 259 16. Chapter Nine: Mitochondria-associated membranes (MAMs) in age-related heart diseases, role of endoplasmic reticulum stress - p. 289 17. Chapter Ten: Cellular senescence and senotherapeutics in cardiovascular diseases - p. 313 18. Chapter Eleven: Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients - p. 351 19. Chapter Twelve: Geropharmacology and gastrointestinal surgery - p. 393 20. Chapter Thirteen: Oxygen-ozone adjunct therapy in aging and senescence-related disorders. State of art - p. 417 21. Chapter Fourteen: Polypharmacy-induced changes in the oral mucosa and jawbone in elderly - p. 447 22. Chapter Fifteen: Senotherapeutic approach to age-related endocrine diseases - p. 475 23. Chapter Sixteen: Polypharmacy as a reason for misinterpreting laboratory results in the elderly - p. 515
